The abstract is read at the publisher; the summary is JClub's.
Consensus guidance for cryptococcal meningitis phase 3 trials recommends 2-week mortality as the primary endpoint, with ≥10-week survival and CSF cryptococcal clearance as key secondary measures.
- Why it matters: Trial endpoints have varied since 1979, limiting standardization and clinical interpretability; this work targets more meaningful, streamlined designs.
- What they did: A joint European Confederation of Medical Mycology–Mycoses Study Group Education and Research Consortium working group reviewed cryptococcosis trials and issued endpoint recommendations for phase 3 and phase 2 studies, including biomarker use and special designs for non-HIV and HIV-associated asymptomatic cryptococcal antigenemia.
- The result: The recommendations provide standardized eligibility criteria and endpoint sets that should improve comparability across cryptococcal meningitis trials and support validated early fungicidal activity readouts in phase 2.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.